Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

<p>Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.</p>

保存先:

書誌詳細
第一著者:	Sebastian Johannes Schober (14971891) (author)
その他の著者:	Caroline Schoening (14971894) (author), Jennifer Eck (14971897) (author), Charlotte Middendorf (14971900) (author), Julia Lutsch (14971903) (author), Pia Knoch (14971906) (author), Anna Josefine von Ofen (14971909) (author), Hendrik Gassmann (14971912) (author), Melanie Thiede (14971915) (author), Julia Hauer (14971918) (author), Andreas Kolk (14971921) (author), Klaus Mantwill (14971924) (author), Jürgen E. Gschwend (14971927) (author), Stefan E.G. Burdach (14971930) (author), Roman Nawroth (14971933) (author), Uwe Thiel (14971936) (author), Per Sonne Holm (14971939) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Immuno-oncology Immunotherapy Combination immunotherapy Pediatric Cancers Sarcomas Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
著者:: Kankan Cao (16437263)
出版事項: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
著者:: Li-Li Long (14963775)
出版事項: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
著者:: Sahar Mafi (16721657)
出版事項: (2025)

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
著者:: Sahar Mafi (16721657)
出版事項: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
著者:: Jian Wang (15048011)
出版事項: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
著者:: Daniel S. Green (15047598)
出版事項: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
著者:: Caroline Robert (15032672)
出版事項: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
著者:: Caroline Robert (15032672)
出版事項: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
著者:: Caroline Robert (15032672)
出版事項: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
著者:: Caroline Robert (15032672)
出版事項: (2025)

Diversity of augmented graphs.
著者:: Hossein Rafieizadeh (22676722)
出版事項: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v9kcjipvc9d2rrqosf89ilr6a7